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Society.Inhibition of human AChE (acetylcholinesterase) and BChE (butyrylcholinesterase) by an
alkylammonium derivative of 6-methyluracil, C-547, a potential drug for the treatment of MG
(myasthenia gravis) was studied. Kinetic analysis of AChE inhibition showed that C-547 is a
slow-binding inhibitor of type B, i.e. after formation of the initial enzyme•inhibitor complex (Ki =
140 pM),  an induced-fit  step allows establishment of  the final  complex (Ki  = 22 pM).  The
estimated koff is low, 0.05 -1 . On the other hand, reversible inhibition of human BChE is a fast-
binding process of mixed-type (Ki = 1.77 μM; Ki = 3.17 μM). The crystal structure of mouse
AChE complexed with C-547 was solved at 3.13 Å resolution. The complex is stabilized by
cation-π , stacking and hydrogenbonding interactions. Molecular dynamics simulations of the
binding/dissociation processes of C-547 and C-35 (a noncharged analogue) to mouse and human
AChEs were performed. Molecular modelling on mouse and human AChE showed that the slow
step results from an enzyme conformational change that allows C-547 to cross the bottleneck in
the  active-site  gorge,  followed  by  formation  of  tight  complex,  as  observed  in  the  crystal
structure. In contrast, the related non-charged compound C-35 is not a slow-binding inhibitor. It
does not cross the bottleneck because it is not sensitive to the electrostatic driving force to
reach the bottom of the gorge. Thus C-547 is one of the most potent and selective reversible
inhibitors of AChE with a long residence time, τ; = 20 min, longer than for other reversible
inhibitors used in the treatment of MG. This makes C-547 a promising drug for the treatment of
this disease.
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